CDK8 and acute myeloid leukemia: Thus, we divided AML cell lines into two classes based on their sensitivity to CDK8 inhibitor treatment (responders and non-responders) and then analyzed levels of phosphorylated STAT1 and STAT5 in these cells (Figure 7D).